FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

Section obligat	this box if no long the state of the second		STA		iled purs	suant	t to Sectio	n 16((a) of the Secu Investment (urities Excha	ange Act of	_	SHIP	Estim		er: 3 verage burder sponse:	3235-0287 1 0.5
1. Name and Address of Reporting Person [*] Alland Leila				2. Issuer Name and Ticker or Trading Symbol <u>PMV Pharmaceuticals, Inc.</u> [PMVP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last)	`	irst) ACEUTICALS,	(Middle) LS, INC.			3. Date of Earliest Transaction (Month/Day/Year) 05/12/2023							X Officer (give title Other (sp below) below) Chief Medical Officer				
ONE RESEARCH WAY			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) PRINCE	TON N	J	08540											led by Mor	•	orting Persor One Repor	I
(City)	(S	itate)	(Zip)		- Rı	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to				
		Tal	ble I - Nor	1-Deri	ivative		-		cquired, D								
1. Title of Security (Instr. 3) Date (Month/D				Execution Date		Code (Instr. 5)			Beneficia Owned F	s Form ally (D) o ollowing (I) (In		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	V Amou	nt (A) (D)	or Price	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)		
									luired, Dis s, options		,		Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Date, T if any C			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	011(3)		
Employee Stock Option (right to buy)	\$5.7	05/12/2023			A		100,000		(1)	05/12/2033	Common Stock	100,000	\$0.00	100,00	00	D	

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.

Remarks:

/s/ Winston Kung, by power of 05/15/2023 <u>attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.